LIFE, US0021202025

aTyr Pharma stock gains 185.71 percent versus Frankfurt close

Published on 10/20/2026 at 19:28 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Q2 net loss reached USD 10.31 million. aTyr Pharma stock costs EUR 0.16 on October 20, 2026, up 185.71 percent versus Frankfurt close.

Price and earnings signals

aTyr Pharma stock gained 185.71 percent against the Frankfurt close on October 20, 2026.
aTyr Pharma reported a USD 10.31 million net loss in the second quarter of 2026.
aTyr Pharma stock costs EUR 0.16 at Lang & Schwarz on October 20, 2026 at 7:17 p.m. CEST, 185.71 percent above the Frankfurt close of October 19, 2026.

LIFE, US0021202025, Illustration mit AI erstellt.

aTyr Pharma (ISIN US0021202025) stock gained 185.71 percent against the Frankfurt close on October 20, 2026, with the euro quote reaching EUR 0.16 at Lang & Schwarz at 7:17 p.m. CEST. The move puts the price EUR 0.10 above the Frankfurt close of October 19, 2026, which was EUR 0.056 before rounding. The calculation uses the German venue because aTyr Pharma is listed on Nasdaq rather than Xetra.

Clinical pipeline remains central

aTyr Pharma is a clinical-stage biotechnology company developing treatments for fibrosis and inflammation. Its lead candidate is efzofitimod, which the company is studying in pulmonary sarcoidosis and systemic sclerosis-related interstitial lung disease, according to aTyr Pharma.

The company also reported a second-quarter net loss of USD 10.31 million, or USD 0.11 per share, for the period ended June 30, 2026. Cash and cash equivalents stood at USD 16.16 million at that date, while operating cash flow was negative USD 9.35 million, according to US Market AI.

Price position and upcoming date

The Nasdaq listing was quoted at USD 0.18 on October 20, 2026, while the same market source showed a 52-week range of USD 0.17 to USD 1.11 on October 19, 2026. The range places the US quote close to its yearly low, although it cannot be compared directly with the euro quotation.

MarketBeat estimates that aTyr Pharma will report third-quarter 2026 results on November 5, 2026, before the market opens. The publication lists a consensus estimate of a USD 0.11 loss per share and revenue of USD 2.50 million for that quarter, compared with a USD 0.26 loss and USD 0.19 million of revenue in the year-earlier quarter, according to MarketBeat.

What the price move changes

The sharp percentage move reflects the very low Frankfurt comparison base rather than a new fundamental valuation measure. For investors, the November reporting date will provide the next scheduled test of cash use, clinical progress and the path toward later-stage development.

Nasdaq listing and euro quote

aTyr Pharma stock was trading at EUR 0.16 at Lang & Schwarz on October 20, 2026 at 7:17 p.m. CEST, 185.71 percent above the Frankfurt close of October 19, 2026 at EUR 0.056. The Nasdaq listing was last quoted at USD 0.18 on October 20, 2026.

The further course of trading is shown by the continuously updated real-time quote of aTyr Pharma stock.